Symbols

VTVT

vTv Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Net Income Decline

Consecutive Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VTVT

Vtv Therapeutics Inc.

A biopharmaceutical company focused on developing oral small molecule treatments for Alzheimer's disease and other central nervous system disorders

Industry

Pharmaceutical

Established Date

04/02/2015

Listing Date

07/30/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.vtvtherapeutics.com

Security Type

Common stock

Office address

3980 Premier Dr, Suite 310, High Point, NC 27265

Business

Introduction

VTv Therapeutics Inc., a holding company, was incorporated in Delaware on April 2, 2015. The Company is a clinical-stage biopharmaceutical company focused on developing oral dosing therapies for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients.

Company Financials

EPS

VTVT has released its 2025 Q2 earnings. EPS was reported at -0.92, versus the expected -0.82, missing expectations. The chart below visualizes how VTVT has performed over recent quarters, highlighting trends in earnings surprises.